Panalgo Blog

ICERvsNICEvenndiagram-300x169
ICER

ICER vs. NICE: Three Key Differences in Approach and Appraisal

Back in December, I recapped an issues panel titled, “Should ICER be NICE (or Not)?” from ISPOR’s 20th Annual European Congress, which sought to compare the use of ICER’s value assessment framework versus NICE’s guidelines when conducting and interpreting cost-effectiveness (CE) analyses. In that post, I summarized the ideas expressed during the[…]

ICERversusNICEpanelatISPOREU-300x225
ICER

ICER Versus NICE: The Verdict From Our ISPOR Glasgow Issue Panel

A smashing success! ISPOR hosted its 20th Annual European Congress in Glasgow, Scotland last month, boasting nearly 5,000 attendees and satisfying our deepest sweet tooth cravings thanks to the lunch menu’s endless supply of teacake biscuits, caramel wafers, caramel shortbread, and IRN Bru. In addition, the conference hosted three well-attended[…]

CEA-Framework-683x1024
ICER

Should ICER Be NICE (or Not)?: A Prelude to Our ISPOR Glasgow Issue Panel

ISPOR’s 20th Annual European Congress in Glasgow is fast approaching, with the first plenary session scheduled for this Monday, November 6th. I will be attending as part of BHE’s team and am looking forward to the plenary sessions discussing the evolution of value in healthcare, including the increase in value-based care initiatives, the future of[…]

ICER

A Need for Alignment: How ICER's New Cost-Effectiveness Framework Compares with the Second Panel's Recommendations

Methodologists in the HEOR community have been busy over the past 9 months. In September 2016, the Second Panel on Cost-Effectiveness in Health and Medicine published a special communication in JAMA (and subsequent hardcover book) that sought to provide guidance for improving the quality of cost-effectiveness (CE) analyses. A few months later in[…]

ICER-Cost-Effectiveness-Ratio-683x1024
ICER

ICER's New Cost-Effectiveness Threshold Raises 5 Major Questions

Early last month the Institute for Clinical and Economic Review (ICER) released a revised Value Assessment Framework for public comment based on feedback received from patients, clinicians, life science companies, and other stakeholders. While a majority of the proposed changes lacked real luster, there is one proposed change that pharma should[…]

Instant Health Data

Put reliable, rapid analytics in the hands of more people across your organization

Learn more about Panalgo

Get the story behind our work and our team.